RECORD | Already taken place We, 11.3.2020
The webinar is a review of the US FDA regulations and present GC/MS analytical methods and strategies for the identification and quantification of nitrosamines.Go to the webinar
GC/MS methods for the accurate determination of nitrosamines produced in the manufacture of APIs and drugs
Agilent Technologies: GC/MS methods for the accurate determination of nitrosamines produced in the manufacture of APIs and drugs
Pharmaceutical impurities, specifically mutagenic impurities in APIs and drug products can significantly affect the stability and efficacy of the drug, and impact safety. Recently, several manufactured lots of Angiotensin II Receptor Blockers (Sartan) and Ranitidine drugs have been recalled due to the presence of high potency mutagenic impurities (nitrosamines) found in these products as a result of a manufacturing process change.
WHAT WILL YOU LEARN
- Understand what mutagenic impurities are and why it's important to characterize and quantify them, even when present in trace amounts.
- Understand the current regulatory guidelines for mutagenic impurity analysis in drug substance and product with an emphasis on nitrosamines in Angiotensin II Receptor Blockers (Sartan) and Ranitidine drug
- Learn about approaches for the confident identification and quantification of nitrosamines in APIs and drugs
WHO SHOULD ATTEND
- Laboratory managers
- Chromatographers
- Analytical chemists and scientists
- New product developers
Presenter: Parul Angrish (PhD Pharma Marketing Manager, Agilent Technologies)
Presenter: Abbey Fausett (Application Chemist, Agilent Technologies)
Presenter: Soma Dasgupta (PhD Application Engineer,GC/GCMS, Agilent Technologies)
